NDAORALTABLET
Approved
Dec 2010
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAFYRAL is an oral contraceptive tablet combining drospirenone and ethinyl estradiol with added levomefolate calcium, a form of folic acid designed to reduce neural tube defect risk in unintended pregnancies. The combination provides contraceptive efficacy through hormonal suppression of ovulation while supplementing folate to support reproductive health. This unique formulation targets women of childbearing age seeking contraception with integrated micronutrient support.
$0.008BPart D
Peak4.1 years to LOEThe product is in peak lifecycle phase with modest Medicare Part D utilization, indicating stable but niche market positioning within the contraceptive landscape.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on SAFYRAL at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.